Meneron Tablets 4mg (Methylprednisolone)

Adult use

The initial dose may vary from 4mg to 48mg of methylprednisolone per day, depending on the symptoms of the specific disease. In general, a low dose is sufficient for less severe conditions, but a high initial dose may be required in certain patients. The initial dose should be maintained or adjusted until a satisfactory response is achieved. If a satisfactory clinical result is not obtained after a reasonable period, discontinue treatment and switch to another appropriate therapy. The dose should be determined individually according to the various diseases being treated and the patient's response. After an adequate response is achieved, determine an appropriate maintenance dose by reducing the initial dose at suitable intervals until the lowest dose that maintains an adequate clinical response is reached. Continuous monitoring of the dose is required. Situations that may require dose adjustment include remission or worsening of the disease, individual patient response to the medicine, and the effect on the patient of exposure to stressful circumstances that are not directly related to the symptoms of the disease being treated. In the latter case, it may be necessary to increase the dose for a period sufficient to achieve satisfactory control of the patient's condition. After long-term treatment, gradual dose reduction is recommended when discontinuing the medicine. For the treatment of acute exacerbations of multiple sclerosis, administration of prednisolone 200mg daily for 1 week followed by prednisolone 80mg every other day for 1 month is effective (4mg of methylprednisolone is equivalent to 5mg of prednisolone). Alternate-day therapy means administering twice the daily dose on one morning every other day. The initial suppressive dose should be continued until a satisfactory clinical response is obtained, usually for 4 to 10 days in many allergic and collagen diseases. ① Switch to ADT and gradually reduce the amount of corticosteroid given every other day. ② Reduce the daily corticosteroid dose to the minimum effective level as soon as possible according to control of disease progression, and then switch to an alternate-day schedule. If this is difficult, it is preferable to administer three times, or even four times, the daily dose every other day rather than simply twice the daily dose. Once the patient is again controlled, attempt to reduce the dose to the lowest level. The adrenal cortex is most active from 2 a.m. to 8 a.m. and least active from 4 p.m. to midnight. When administered during the period of peak activity (in the morning), exogenous corticosteroids suppress adrenal cortical activity the least. If an acute exacerbation occurs during disease progression, it may be necessary to return to a divided daily corticosteroid dose that provides complete suppression to achieve control. Once controlled, the established alternate-day regimen may be tried again.

This drug should not be used in patients with allergies to this drug or its components. Caution is required when administering to patients with infections or systemic fungal infections, as immunosuppression may worsen infections. This drug should not be given to patients with herpes simplex, herpes zoster, or chickenpox, nor to those receiving live or attenuated live vaccines. Since this drug contains lactose, it should not be administered to patients with genetic issues such as galactose intolerance, lactose deficiency, or glucose-galactose malabsorption. Patients with glaucoma, tuberculous disease, cataracts, hypertension, thrombosis, or those who have recently undergone bowel anastomosis must use this drug cautiously, and administration should be based on a physician's judgment due to the possibility of worsening symptoms. Diabetic patients should strictly manage blood sugar levels as this drug can increase blood sugar. Patients with renal failure, congestive heart failure, hypothyroidism, fatty liver, and other specific diseases must also be cautious. Various side effects such as edema, muscle weakness, gastrointestinal disturbances, skin changes, neuropsychiatric symptoms, and endocrine abnormalities may occur during treatment, so symptoms should be closely monitored. Long-term use may lead to adrenal insufficiency or withdrawal symptoms; therefore, sudden discontinuation should be avoided, and the dosage should be gradually reduced. Due to the immunosuppressive effect, the risk of infection may increase, so exposure to chickenpox or measles should be avoided, and medical consultation is necessary if infection is suspected. Drug interactions may occur when used in combination with other medications, so any concurrent medications should be disclosed, especially with heart-related drugs, antibiotics, and diuretics. Pregnant women or women who may become pregnant should only use this drug after consulting a doctor due to potential effects on the fetus. For breastfeeding women, it is recommended to cease breastfeeding. In children, side effects such as growth retardation may occur, so it should be administered cautiously at the minimum effective dose, and growth status should be carefully monitored. Elderly patients may be at higher risk for side effects such as infections, diabetes, osteoporosis, and glaucoma, requiring more careful observation and management. Regular consultations with a doctor and necessary tests during treatment with this drug are advised for safety.

Edema, sodium retention, potassium loss, fluid retention, hypokalemic alkalosis, congestive heart failure, hypertension, myasthenia, aseptic necrosis of the femoral and humeral epiphyses, steroid myopathy, loss of muscle mass, pathological fractures of the pelvis, osteoporosis, vertebral compression fracture, arthralgia, tendon rupture, increased ALT, increased AST, increased ALP, nausea, thirst, vomiting, gastric pain, loss of appetite, increased appetite, peptic ulcer, abdominal bloating, pancreatitis, esophagitis, diarrhea, delayed wound healing, facial erythema, thin and fragile skin, abnormal sweating, petechiae, ecchymosis, suppression of skin reactions, purpura, acne, hirsutism, alopecia, pigmentation, nipple edema, increased intracranial pressure, convulsions, dizziness, headache, insomnia, euphoria, depression, Cushing's syndrome, menstrual irregularities, growth suppression in children, latent diabetes symptoms, secondary adrenal insufficiency, pituitary non-responsiveness, decreased glucose tolerance, increased requirement for insulin or oral hypoglycemic agents, suppression of adrenocorticotropic hormone secretion, increased intraocular pressure, glaucoma, posterior subcapsular cataract, secondary eye infections, central serous chorioretinopathy, retinal disorders, exophthalmos, negative nitrogen balance due to protein catabolism, immune system disorders, allergic reactions, shock, urticaria, anaphylactic reactions, hypersensitivity reactions

This drug should be stored in a tightly closed container to prevent exposure to air or moisture. It is recommended to maintain a storage temperature between 1°C and 30°C room temperature. This helps preserve the drug's effectiveness for a longer period.

Appearance

White oval tablet

Package unit

(For domestic use) - 30 tablets/bottle, (For domestic use) - 300 tablets/bottle